法尼醇X受体在治疗胆汁淤积性肝病中的作用机制和药物研究进展

被引:3
作者
胡莉 [1 ]
杨伟峰 [2 ]
刘婷 [1 ]
冯伟红 [1 ]
卢晨娜 [1 ]
李春 [1 ]
机构
[1] 中国中医科学院中药研究所
[2] 中国中医科学院医学实验中心
基金
国家重点研发计划;
关键词
胆汁淤积性肝病; 法尼醇X受体; 法尼醇X受体激动剂; 法尼醇X受体拮抗剂;
D O I
10.19803/j.1672-8629.20240531
中图分类号
R575 [肝及胆疾病];
学科分类号
100201 [内科学];
摘要
目的 综述法尼醇X受体(FXR)在治疗胆汁淤积性肝病中的作用机制及以FXR为靶点的药物研究进展。方法 对FXR通过调控胆汁酸的生成、代谢、转运以及肠肝循环等方式改善胆汁淤积的机制进行阐述,对FXR具有的抗炎、抗氧化和抗肝纤维化等作用和机制进行论述,对甾体和非甾体类FXR激动剂和FXR拮抗剂的治疗效果和临床试验进展进行综述。结果与结论 胆汁淤积性肝病是以胆汁淤积为主要表现的一组临床常见疾病,其致病机制复杂,也一定程度上决定了用药的复杂性。核受体能调控胆汁酸体内平衡,是目前胆汁淤积治疗药物靶标的研究热点;FXR在保持胆汁酸平衡方面起着至关重要的作用,是一种生理性的胆汁酸核受体,被视为胆汁淤积和相关疾病的主要治疗靶点。随着对FXR研究的不断深入,发现其在胆汁酸稳态、抗炎、抗氧化、抗纤维化方面发挥核心调控作用,FXR激动剂和FXR拮抗剂不断被研发以治疗胆汁淤积性肝病。
引用
收藏
页码:1184 / 1191+1199 +1199
页数:9
相关论文
共 47 条
[1]
Sarmentol H derived from Sedum sarmentosum Bunge directly targets FXR to mitigate cholestasis by recruiting SRC-1.[J].Zhenxiu Liu;Lin Chen;Mingyun Chen;Lang Linghu;Zhihua Liao;Min Chen;Guowei Wang.Phytomedicine.2024,
[2]
Macrophage polarization: an important role in inflammatory diseases.[J].Min Luo;Fukun Zhao;Huan Cheng;Mu Su;Yuanmin Wang.Frontiers in Immunology.2024,
[3]
Evolutionary analysis of SLC10 family members and insights into function and expression regulation of lamprey NTCP [J].
Zhu, Yingying ;
Zhang, Qipeng ;
Pan, Jilong ;
Li, Tiesong ;
Wang, Hao ;
Liu, Jindi ;
Qian, Lei ;
Zhu, Ting ;
Pang, Yue ;
Li, Qingwei ;
Chi, Yan .
FISH PHYSIOLOGY AND BIOCHEMISTRY, 2024, 50 (03) :1109-1122
[4]
The discovery of a new potent FXR agonist based on natural product screening [J].
Yao, Zongwen ;
Chen, Lin ;
Hu, Min ;
Meng, Fancheng ;
Chen, Min ;
Wang, Guowei .
BIOORGANIC CHEMISTRY, 2024, 143
[5]
Targeting the FGF19-FGFR4 pathway for cholestatic; metabolic; and cancerous diseases..[J].Xiaokun Li;Weiqin Lu;Alexei Kharitonenkov;Yongde Luo.Journal of internal medicine.2024,
[6]
JiaGaSongTang improves chronic cholestasis via enhancing FXR-mediated bile acid metabolism..[J].Xiaoliang He;Yingya Zhou;Jingtao Yu;Qinpo Huang;Zhengyuan Chen;Ru Xiao;Changhui Liu;Shuhua Gui;Tianqin Xiong.Phytomedicine : international journal of phytotherapy and phytopharmacology.2024,
[7]
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis [J].
Trauner, Michael ;
Chung, Chuhan ;
Sterling, Kate ;
Liu, Xiangyu ;
Lu, Xiaomin ;
Xu, Jun ;
Tempany-Afdhal, Clare ;
Goodman, Zachary D. ;
Faerkkilae, Martti ;
Tanaka, Atsushi ;
Trivedi, Palak ;
Kowdley, Kris V. ;
Bowlus, Christopher L. ;
Levy, Cynthia ;
Myers, Robert P. .
BMC GASTROENTEROLOGY, 2023, 23 (01)
[8]
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial [J].
Sanyal, Arun J. ;
Lopez, Patricia ;
Lawitz, Eric J. ;
Lucas, Kathryn J. ;
Loeffler, Juergen ;
Kim, Won ;
Goh, George B. B. ;
Huang, Jee-Fu ;
Serra, Carla ;
Andreone, Pietro ;
Chen, Yi-Cheng ;
Hsia, Stanley H. ;
Ratziu, Vlad ;
Aizenberg, Diego ;
Tobita, Hiroshi ;
Sheikh, Aasim M. ;
Vierling, John M. ;
Kim, Yoon Jun ;
Hyogo, Hideyuki ;
Tai, Dean ;
Goodman, Zachary ;
Schaefer, Felicity ;
Carbarns, Ian R. I. ;
Lamle, Sophie ;
Martic, Miljen ;
Naoumov, Nikolai V. ;
Brass, Clifford A. .
NATURE MEDICINE, 2023, 29 (02) :392-+
[9]
Stimulation of the farnesoid X receptor promotes M2 macrophage polarization
.[J].Jaroonwitchawan Thiranut;Arimochi Hideki;Sasaki Yuki;Ishifune Chieko;Kondo Hiroyuki;Otsuka Kunihiro;Tsukumo Shin ichi;Yasutomo Koji.Frontiers in Immunology.2023,
[10]
The Role of Inflammation in Cholestatic Liver Injury [J].
Chen, Jie ;
Zhang, Shujun .
JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 :4527-4540